Osteopenia Treatment Guidelines

Initial Assessment and Risk Stratification

The American College of Physicians recommends treatment decisions for osteopenia be based on individualized fracture risk assessment using FRAX or clinical risk factors, with bisphosphonate therapy recommended when 10-year major osteoporotic fracture risk is ≥20% or hip fracture risk is ≥3% 1
For a 71-year-old woman with osteopenia, the presence of additional risk factors such as history of fragility fracture, low body weight, parental history of hip fracture, current smoking, corticosteroid use, and decreased physical activity may indicate a need for treatment 2

All women with osteopenia should receive calcium supplementation of 1,200 mg daily and vitamin D supplementation of 800 IU daily, as well as engage in weight-bearing exercise, smoking cessation, and reduction of alcohol intake 3, 4

Bisphosphonate therapy is recommended for patients with a FRAX score indicating ≥20% risk of major osteoporotic fracture or ≥3% risk of hip fracture over 10 years, with oral options including alendronate, risedronate, and ibandronate, and intravenous option zoledronic acid 1, 4, 6
The American College of Physicians recommends bisphosphonates as the first-line therapy for osteopenia, due to their favorable balance of benefits, harms, and cost 6

Initial treatment duration with bisphosphonates should be 5 years, after which fracture risk should be reassessed to determine if continuation is needed 6, 9
Patients at low fracture risk should be considered for drug discontinuation after 3-5 years 10, 1

Short-term adverse effects of bisphosphonates include upper GI symptoms, influenza-like symptoms, and hypocalcemia 2, 5, 6
Long-term adverse effects include atypical femoral fractures and osteonecrosis of the jaw, which are rare but increased with longer duration of treatment 3, 6